4.7 Review

Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

期刊

CANCER DISCOVERY
卷 2, 期 3, 页码 214-226

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0012

关键词

-

类别

资金

  1. NIH Director's New Innovator Award
  2. Lung Cancer SPORE [P50 CA090578, R01CA135257]
  3. Starr Cancer Consortium
  4. Melanoma Research Alliance

向作者/读者索取更多资源

All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s). Significance: Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways. Cancer Discovery; 2(3); 214-26. (c) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据